Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LOXAPINE SUCCINATE

4 general benefit · 4 not a benefit

Other products in the same Health Canada class (N05A, N05AH) — coverage varies; not interchangeable

  • Asenapine (Saphris): general benefit
  • Olanzapine (Zyprexa Zydis): general benefit, Not a benefit
  • Quetiapine (Seroquel XR): general benefit, Not a benefit
  • Clozapine (AA-Clozapine Tablet): not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Xylac · DIN 02230838 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Xylac · DIN 02230838 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1999-04-15 Health Canada: Marketed since 2013-09-20 · brand XYLAC · ATC N05AH01 LOXAPINE · form Tablet · route Oral · ingredients LOXAPINE (LOXAPINE SUCCINATE) 10 MG · company Pendopharm division of pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Xylac: Formulary list price $0.3233/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3233 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50116 · Verify on the e-Formulary ↗ (DIN 02230838)

Source record
DIN 02230838: Xylac Raw flags: sec3=Y Item: 281608242; group id 496; item number 1273; lccId None; manufacturer id PEN Source form: Tab; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.3233; ministry $0.3233 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230838 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50116
Interchangeable products
Loxapac · DIN 02170027 · not recorded
Shortage status: resolved shortage (ended 2024-10-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230838
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xylac · DIN 02230839 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Xylac · DIN 02230839 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1999-04-15 Health Canada: Marketed since 2013-11-11 · brand XYLAC · ATC N05AH01 LOXAPINE · form Tablet · route Oral · ingredients LOXAPINE (LOXAPINE SUCCINATE) 25 MG · company Pendopharm division of pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Xylac: Formulary list price $0.5012/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.5012 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50117 · Verify on the e-Formulary ↗ (DIN 02230839)

Source record
DIN 02230839: Xylac Raw flags: sec3=Y Item: 281608243; group id 496; item number 1274; lccId None; manufacturer id PEN Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.5012; ministry $0.5012 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230839 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50117
Interchangeable products
Loxapac · DIN 02170132 · not recorded
Shortage status: resolved shortage (ended 2024-05-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230839
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Xylac · DIN 02230837 · 5mg · tablet

General benefitDormant since 2018-07-05 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Xylac · DIN 02230837 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1999-04-15 Health Canada: Dormant since 2018-07-05 · brand XYLAC · ATC N05AH01 LOXAPINE · form Tablet · route Oral · ingredients LOXAPINE (LOXAPINE SUCCINATE) 5 MG · company Pendopharm division of pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Xylac: Formulary list price $0.1801/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1801 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50115 · Verify on the e-Formulary ↗ (DIN 02230837)

Source record
DIN 02230837: Xylac Raw flags: sec3=Y Item: 281608241; group id 496; item number 1272; lccId None; manufacturer id PEN Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $0.1801; ministry $0.1801 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230837 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50115
Interchangeable products
Loxapac · DIN 02170019 · not recorded
Shortage status: resolved shortage (ended 2018-09-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230837
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2018-07-05 — choose a marketed DIN from the same-category list.

Xylac · DIN 02230840 · 50mg · tablet

General benefitDormant since 2018-04-06 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Xylac · DIN 02230840 Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 1999-04-15 Health Canada: Dormant since 2018-04-06 · brand XYLAC · ATC N05AH01 LOXAPINE · form Tablet · route Oral · ingredients LOXAPINE (LOXAPINE SUCCINATE) 50 MG · company Pendopharm division of pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

Xylac: Formulary list price $0.6197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50120 · Verify on the e-Formulary ↗ (DIN 02230840)

Source record
DIN 02230840: Xylac Raw flags: sec3=Y Item: 281608244; group id 496; item number 1275; lccId None; manufacturer id PEN Source form: Tab; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.6197; ministry $0.6197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02230840 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=50120
Interchangeable products
Loxapac · DIN 02170035 · not recorded
Shortage status: resolved shortage (ended 2018-09-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02230840
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2018-04-06 — choose a marketed DIN from the same-category list.

Loxapac · DIN 02170019 · 5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-31 — choose a marketed DIN from the same-category list.Discontinued 2002-07-31 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Loxapac · DIN 02170019 Manufacturer: Wyeth Pharmaceuticals; listing date 1998-03-17 Health Canada: Cancelled post market since 2002-07-31 · brand LOXAPAC - TAB 5MG · ATC N05AH01 LOXAPINE · form Tablet · route Oral · ingredients LOXAPINE (LOXAPINE SUCCINATE) 5 MG · company Wyeth-ayerst canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Loxapac: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34562 · Verify on the e-Formulary ↗ (DIN 02170019)

Source record
DIN 02170019: Loxapac Raw flags: notABenefit=Y, sec3=Y Item: 281608241; group id 496; item number 1272; lccId None; manufacturer id WAY Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02170019 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34562
Interchangeable products
Xylac · DIN 02230837 · $0.1801
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02170019
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-07-31 — choose a marketed DIN from the same-category list.

Loxapac · DIN 02170027 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-02-06 — choose a marketed DIN from the same-category list.Discontinued 2002-02-06 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-02-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-02-06 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Loxapac · DIN 02170027 Manufacturer: Wyeth Pharmaceuticals; listing date 1998-11-19 Health Canada: Cancelled post market since 2002-02-06 · brand LOXAPAC - TAB 10MG · ATC N05AH01 LOXAPINE · form Tablet · route Oral · ingredients LOXAPINE (LOXAPINE SUCCINATE) 10 MG · company Wyeth-ayerst canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Loxapac: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34563 · Verify on the e-Formulary ↗ (DIN 02170027)

Source record
DIN 02170027: Loxapac Raw flags: notABenefit=Y, sec3=Y Item: 281608242; group id 496; item number 1273; lccId None; manufacturer id WAY Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02170027 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34563
Interchangeable products
Xylac · DIN 02230838 · $0.3233
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02170027
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-02-06 — choose a marketed DIN from the same-category list.

Loxapac · DIN 02170132 · 25mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-03-19 — choose a marketed DIN from the same-category list.Discontinued 2002-03-19 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-03-19 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-03-19 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Loxapac · DIN 02170132 Manufacturer: Wyeth Pharmaceuticals; listing date 1998-11-19 Health Canada: Cancelled post market since 2002-03-19 · brand LOXAPAC TABLETS - 25 MG · ATC N05AH01 LOXAPINE · form Tablet · route Oral · ingredients LOXAPINE (LOXAPINE SUCCINATE) 25 MG · company Wyeth-ayerst canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Loxapac: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34573 · Verify on the e-Formulary ↗ (DIN 02170132)

Source record
DIN 02170132: Loxapac Raw flags: notABenefit=Y, sec3=Y Item: 281608243; group id 496; item number 1274; lccId None; manufacturer id WAY Source form: Tab; strength: 25mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02170132 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34573
Interchangeable products
Xylac · DIN 02230839 · $0.5012
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02170132
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2002-03-19 — choose a marketed DIN from the same-category list.

Loxapac · DIN 02170035 · 50mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-05-22 — choose a marketed DIN from the same-category list.Discontinued 2001-05-22 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-05-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-05-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Loxapac · DIN 02170035 Manufacturer: Wyeth Pharmaceuticals; listing date 1998-03-17 Health Canada: Cancelled post market since 2001-05-22 · brand LOXAPAC - TAB 50MG · ATC N05AH01 LOXAPINE · form Tablet · route Oral · ingredients LOXAPINE (LOXAPINE SUCCINATE) 50 MG/TAB · company Wyeth-ayerst canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Loxapac: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34564 · Verify on the e-Formulary ↗ (DIN 02170035)

Source record
DIN 02170035: Loxapac Raw flags: notABenefit=Y, sec3=Y Item: 281608244; group id 496; item number 1275; lccId None; manufacturer id WAY Source form: Tab; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02170035 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34564
Interchangeable products
Xylac · DIN 02230840 · $0.6197
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02170035
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2001-05-22 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

OLANZAPINE

· 116 products · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) · strengths: 5mg, 10mg, 15mg, 20mg, 2.5mg, 7.5mg · Rapid Dissolve Tab, Tab

QUETIAPINE

· 128 products · General benefit (125), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 50mg, 150mg, 200mg, 300mg, 400mg, 25mg, 100mg · ER Tab, Tab

CLOZAPINE

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 200mg, 25mg, 100mg ·

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS XYLAC (loxapine succinate tablets) is indicated in the management of the manifestations of schizophrenia. 1.1 Pediatrics Pediatrics (under 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (over 65 years of age): Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. XYLAC is not indicated for the treatment of elderly patients with dementia. (See 3 SERIOUS WARNINGS AND PRECAUTIONS BOX and 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations, 7.1.4 Geriatrics.) https://pdf.hres.ca/dpd_pm/00059742.PDF PM date: January 26, 2021 Source product: XYLAC; DIN 02230838; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Loxapac: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026